NCT01582698

TBE Seropersistence up to 10 Years After First Booster in Adults

Open-label Phase 4 Study to Investigate the Seropersistence of Tick-borne Encephalitis (TBE) Virus Antibodies From 7 to 10 Years After the First Booster and the Response to a Second Booster Vaccination With FSME-IMMUN 0.5ml in Adults

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 243 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 25 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.

Conditions

• Tick-borne Encephalitis (TBE)

Interventions

Type	Name	Description
BIOLOGICAL	FSME-IMMUN 0.5 ml	Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.

Timeline

• Start date: 2012-04-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2012-04-23
• Last updated: 2021-01-22

Locations

2 sites across 1 country: Poland